A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

NCT07221669 | Recruiting Phase 3 DMC FDA Drug

• 2 other identifiers: 277SM3022025-523116-37
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 2

Brief Summary

In this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about how salanersen works in babies who have been diagnosed with SMA through genetic testing but have not yet started showing signs or symptoms. Most people with SMA have changes in a gene called survival motor neuron 1, also known as SMN1. These changes lower the amount of SMN protein in their bodies. Without enough of this protein, motor neurons and muscles cannot work properly. A similar gene called SMN2 can help replace some of the lost SMN protein in the body. Salanersen works by helping the SMN2 gene to make more SMN protein. In this study, participants will have either 2 SMN2 copies or 3 SMN2 copies. The higher the copy number, the less severe the participant's SMA is. The main goal of this study is to see if starting salanersen before signs or symptoms appear can prevent signs or symptoms of SMA or make them less severe. Researchers will use different tests to learn if motor symptoms are changing, including the World Health Organization (WHO) motor milestones. The main questions researchers want to answer in this study are:

• How many participants with 2 copies of the SMN2 gene can sit without support at 12 months?
• How many participants with 3 copies of the SMN2 gene can walk alone at 18 months? Researchers will also learn more about:
• The effects on participants' motor symptoms and how many new movement milestones participants achieve.
• How many participants stay free of SMA symptoms
• How much salanersen gets into the fluid surrounding the brain and spinal cord.
• How much salanersen gets into the blood.
• How many participants have adverse events or serious adverse events. Adverse events are health problems that may or may not be caused by the study drug. This study will be done as follows:
• First, participants will be screened to check if they can join the study. The screening period will be up to 28 days.
• This is an "open label" study. This is a study in which the participants, study doctor, and site staff know which study drug participants are receiving. In this study, all participants will receive salanersen through an intrathecal injection, or one that is given into the fluid surrounding the brain and spinal cord.
• There will be 2 parts in this study. During Part 1, participants will receive 2 doses of salanersen, about 12 months apart from each other. Part 1 will last up to 25 months.
• During Part 2, participants will continue to receive salanersen. They will receive up to 3 doses, 12 months apart from each other. Part 2 will last up to 36 months.
• During Part 1, participants will have up to 11 clinic visits and up to 3 phone calls. During Part 2, participants will have up to 7 clinic visits and up to 12 phone calls.

Conditions

Muscular Atrophy, Spinal

Outcome Measures

Primary Outcomes (3)

• Part 1: Percentage of Participants with 2 Survival Motor Neuron 2 (SMN2) Copies Sitting Without Support (for at Least 10 Seconds)

  At Month 12

• Part 1: Percentage of Participants with 3 SMN2 Copies Walking Alone (for at Least 5 Steps)

  At Month 18

• Part 2: Percentage of Participants Attaining and Maintaining World Health Organization (WHO) Motor Milestones

  The WHO motor milestones will include six key developmental milestones: sitting without support, standing with assistance, hands-and-knees crawling, walking with assistance, standing alone, and walking alone.

  Up to Day 1825

Secondary Outcomes (16)

• Part 1: Percentage of Participants Attaining World Health Organization (WHO) Motor Milestones

  Up to Day 730

• Parts 1 and 2: Percentage of Participants Attaining Hammersmith Infant Neurological Examination Section 2 (HINE-2) Motor Milestones

  Up to Day 1825

• Parts 1 and 2: Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale

  Up to Day 1825

• Parts 1 and 2: Change From Baseline in Compound Muscle Action Potential (CMAP) Amplitudes

  Up to Day 1825

• Part 1: Percentage of Participants who Remain Free of Clinically Manifested Spinal Muscular Atrophy (SMA)

  Up to Day 730

Study Arms (1)

Salanersen

EXPERIMENTAL

In Part 1 of the study, participants will receive two doses of salanersen, 80 milligrams (mg) by intrathecal (IT) lumbar puncture (LP), approximately 12 months apart. Participants who complete Part 1 of the study will receive three doses of salanersen, 80 mg by IT LP, approximately 12 months apart, in Part 2 of the study.

Drug: Salanersen

Interventions

Salanersen DRUG

Administered intrathecally

Also known as: BIIB115

Salanersen

Eligibility Criteria

• Age: 0 Days - 42 Days
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• ≤42 days of age at first dose of salanersen.
• Genetic documentation of 5q SMA homozygous gene deletion or mutation or compound heterozygous mutation.
• Two or three copies of the survival motor neuron 2 (SMN2) gene.
• Ulnar compound muscle action potential (CMAP) amplitude ≥2 millivolt (mV) at Screening and Day 1 predose.
• Body weight ≥3rd percentile for age based on World Health Organization (WHO) Child Growth Standards at the time of informed consent.

You may not qualify if:

• Any clinical signs or symptoms at Screening or Day 1 predose that are, in the opinion of the Investigator, strongly suggestive of SMA.
• Areflexia on neurologic examination at biceps, knee, or ankle at Screening or Day 1 Predose.
• Hypoxemia (oxygen saturation \<96% awake or asleep without any supplemental oxygen or respiratory support, or for altitudes \>1000 meters (m), oxygen saturation of \<92% awake or asleep without any supplemental oxygen or respiratory support).
• Diagnosis of neonatal respiratory distress syndrome necessitating surfactant replacement therapy or invasive ventilatory support.
• Any reason, anatomical or otherwise (including hematology/coagulation laboratory results), that presents increased risk of complication from the LP procedures or safety assessments.
• Any prior treatment with an approved SMA disease-modifying therapy (e.g., nusinersen, onasemnogene abeparvovec-xioi \[OA\], and/or risdiplam), a myostatin inhibitor therapy, or an investigational drug given for the treatment of SMA.

Sponsors & Collaborators

• Biogen: lead

Study Sites (2)

Neurology Rare Disease Center

Flower Mound, Texas, 75028, United States

RECRUITING

Childrens Hospital of the Kings Daughter Norfolk

Norfolk, Virginia, 23507, United States

RECRUITING

Related Links

• Related Info

MeSH Terms

Conditions

Muscular Atrophy, Spinal

Condition Hierarchy (Ancestors)

Spinal Cord Diseases; Central Nervous System Diseases; Nervous System Diseases; Motor Neuron Disease; Neurodegenerative Diseases; Neuromuscular Diseases

Study Officials

• Medical Director

  Biogen

  STUDY DIRECTOR

Central Study Contacts

US Biogen Clinical Trial Center

CONTACT

866-633-4636; clinicaltrials@biogen.com

Global Biogen Clinical Trial Center

CONTACT

clinicaltrials@biogen.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 24, 2025
• First Posted: October 28, 2025
• Study Start: April 28, 2026
• Primary Completion (Estimated): November 28, 2028
• Study Completion (Estimated): May 29, 2032
• Last Updated: May 6, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share

Locations

US (2)